RU2630619C2 - Фармацевтические композиции, содержащие карбамоилоксиарилалканоиларилпиперазиновое соединение - Google Patents

Фармацевтические композиции, содержащие карбамоилоксиарилалканоиларилпиперазиновое соединение Download PDF

Info

Publication number
RU2630619C2
RU2630619C2 RU2013102958A RU2013102958A RU2630619C2 RU 2630619 C2 RU2630619 C2 RU 2630619C2 RU 2013102958 A RU2013102958 A RU 2013102958A RU 2013102958 A RU2013102958 A RU 2013102958A RU 2630619 C2 RU2630619 C2 RU 2630619C2
Authority
RU
Russia
Prior art keywords
acid
dimethoxyphenyl
piperazin
ester
carbamic acid
Prior art date
Application number
RU2013102958A
Other languages
English (en)
Russian (ru)
Other versions
RU2013102958A (ru
Inventor
Хон Сик МУН
Хань Цзу ЙИ
Ын Хи ЧХЕ
Сан Ми ЧХЕ
Хье Вон ШИНЬ
Original Assignee
СК Биофармасьютикалз Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by СК Биофармасьютикалз Ко., Лтд. filed Critical СК Биофармасьютикалз Ко., Лтд.
Publication of RU2013102958A publication Critical patent/RU2013102958A/ru
Application granted granted Critical
Publication of RU2630619C2 publication Critical patent/RU2630619C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/66—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2013102958A 2010-07-08 2011-07-08 Фармацевтические композиции, содержащие карбамоилоксиарилалканоиларилпиперазиновое соединение RU2630619C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2010-0065950 2010-07-08
KR1020100065950A KR101810975B1 (ko) 2010-07-08 2010-07-08 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물
PCT/KR2011/004996 WO2012005536A2 (fr) 2010-07-08 2011-07-08 Compositions pharmaceutiques comprenant un composé de carbamoyloxy- arylalcanoyl-arylpipérazine

Publications (2)

Publication Number Publication Date
RU2013102958A RU2013102958A (ru) 2014-08-20
RU2630619C2 true RU2630619C2 (ru) 2017-09-11

Family

ID=45441670

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013102958A RU2630619C2 (ru) 2010-07-08 2011-07-08 Фармацевтические композиции, содержащие карбамоилоксиарилалканоиларилпиперазиновое соединение

Country Status (14)

Country Link
US (2) US8648083B2 (fr)
EP (1) EP2590650A4 (fr)
JP (3) JP5985472B2 (fr)
KR (1) KR101810975B1 (fr)
CN (1) CN103096892B (fr)
AU (1) AU2011274665B2 (fr)
BR (1) BR112013000532A2 (fr)
CA (1) CA2803580C (fr)
CL (1) CL2013000034A1 (fr)
HK (1) HK1181305A1 (fr)
MX (1) MX2012015015A (fr)
RU (1) RU2630619C2 (fr)
WO (1) WO2012005536A2 (fr)
ZA (1) ZA201209631B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140198A1 (fr) * 2007-05-14 2008-11-20 Sk Holdings Co., Ltd. Nouveau composé carbamoyloxy arylalcanoyl arylpipérazine, compositions pharmaceutiques comprenant ce composé et méthode de traitement de la douleur, de l'anxiété et de la dépression comprenant l'administration de ce composé
KR101810975B1 (ko) 2010-07-08 2017-12-20 에스케이바이오팜 주식회사 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물
RU2702117C1 (ru) * 2016-01-27 2019-10-04 Бориюнг Фармасьютикал Ко., Лтд. Фармацевтическая композиция для предупреждения или лечения диабетической нефропатии
BR112020013140A2 (pt) * 2017-12-28 2020-12-01 Reviva Pharmaceuticals, Inc. método para tratar fibrose pulmonar em um indivíduo.

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140198A1 (fr) * 2007-05-14 2008-11-20 Sk Holdings Co., Ltd. Nouveau composé carbamoyloxy arylalcanoyl arylpipérazine, compositions pharmaceutiques comprenant ce composé et méthode de traitement de la douleur, de l'anxiété et de la dépression comprenant l'administration de ce composé
US20090181967A1 (en) * 2007-12-05 2009-07-16 Biovitrum Ab New compounds I

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001261269A1 (en) 2000-06-14 2001-12-24 Warner Lambert Company 1,2,4-trisubstituted benzenes as inhibitors of 15-lipoxygenase
ZA200803636B (en) * 2005-10-31 2009-10-28 Biolipox Ab Triazole compounds as lipoxygenase inhibitors
KR20080040393A (ko) 2006-11-03 2008-05-08 정수환 소스 라우팅 기반의 이동 애드 혹 네트워크에서 안전한데이터 전송 방법
WO2011093776A1 (fr) * 2010-01-28 2011-08-04 Ge Healthcare Bio-Sciences Ab Colonne pour chromatographie en phase liquide
KR101810975B1 (ko) 2010-07-08 2017-12-20 에스케이바이오팜 주식회사 카바모일옥시 아릴알칸노일 아릴피페라진계 화합물을 포함하는 약학적 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140198A1 (fr) * 2007-05-14 2008-11-20 Sk Holdings Co., Ltd. Nouveau composé carbamoyloxy arylalcanoyl arylpipérazine, compositions pharmaceutiques comprenant ce composé et méthode de traitement de la douleur, de l'anxiété et de la dépression comprenant l'administration de ce composé
WO2008140197A1 (fr) * 2007-05-14 2008-11-20 Sk Holdings Co., Ltd. Nouveau composé carbamoyloxy aryle alcane arylpipérazine, compositions pharmaceutiques comprenant ce composé et méthode de traitement de la douleur, de l'anxiété et de la dépression par administration de ce composé
US20090181967A1 (en) * 2007-12-05 2009-07-16 Biovitrum Ab New compounds I

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Энциклопедический словарь медицинских терминов, Изд.второе., под ред. В.И. Покровского, М.:Медицина,2011, стр.167-168, словарная статья "Воспаление". Беликов В.Г., Фармацевтическая химия. Глава 2.2. "Связь между структурой молекул веществ и их действием на организм". М.: Высшая школа, 1993, с. 43-47. *

Also Published As

Publication number Publication date
CL2013000034A1 (es) 2013-10-04
WO2012005536A2 (fr) 2012-01-12
US8648083B2 (en) 2014-02-11
ZA201209631B (en) 2014-03-26
US20130131081A1 (en) 2013-05-23
BR112013000532A2 (pt) 2016-06-07
CN103096892B (zh) 2015-08-12
AU2011274665A1 (en) 2013-01-17
JP5985472B2 (ja) 2016-09-06
EP2590650A2 (fr) 2013-05-15
JP2016193901A (ja) 2016-11-17
RU2013102958A (ru) 2014-08-20
US9238633B2 (en) 2016-01-19
JP2013536161A (ja) 2013-09-19
MX2012015015A (es) 2013-02-07
EP2590650A4 (fr) 2014-01-08
AU2011274665B2 (en) 2015-01-15
KR101810975B1 (ko) 2017-12-20
CA2803580C (fr) 2018-05-01
KR20120005286A (ko) 2012-01-16
US20140243352A1 (en) 2014-08-28
WO2012005536A3 (fr) 2012-04-05
JP2018058855A (ja) 2018-04-12
JP6562522B2 (ja) 2019-08-21
CA2803580A1 (fr) 2012-01-12
CN103096892A (zh) 2013-05-08
HK1181305A1 (en) 2013-11-08

Similar Documents

Publication Publication Date Title
JP6562522B2 (ja) カルバモイルオキシアリールアルカノイルアリールピペラジン化合物を含む医薬組成物
TWI729443B (zh) 做為組蛋白去乙醯酶6抑制劑之1,3,4-㗁二唑衍生物及包含彼之醫藥組合物
EP3572404A1 (fr) Hétérocomplexe de butylphthalide-telmisartan, procédé de préparation et application associés
EP2945702B1 (fr) Dérivés d'éther d'aminoalkyle de phenyle substitués par substituents hydroxy aliphatique
WO2008062830A1 (fr) Composé de spiroquinone et composition pharmaceutique
WO2008044729A1 (fr) Dérivé d'acide carboxylique
JPS60116657A (ja) アニリン誘導体
EP0929550A1 (fr) DERIVES DE $i(N)-(BENZOTHIAZOL-2-YL)PIPERIDINE-1-ETHANAMINE, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
JPH02229168A (ja) ピラゾロン誘導体
CN113387909B (zh) 2,3-环氧丁二酰衍生物的医药用途
KR100903974B1 (ko) 2,4,5-삼중치환-1,3-티아졸 유도체 및 약제학적으로 허용가능한 그의 염, 그의 제조방법 및 그를 유효성분으로함유하는 ｓｐｃ 수용체 활성으로 유발되는 염증관련 질환치료제
FR2892722A1 (fr) Composes de type methanone et leur utilisation dans des compositions pharmaceutiques notamment pour le traitement des maladies cardiovasculaires
KR100703598B1 (ko) 리폭시제나아제에 대한 저해 활성을 갖는 신규벤즈옥사졸 아미드 유도체 화합물, 이의 제조방법 및 이를포함하는 천식의 치료 및 예방용 조성물
KR101051078B1 (ko) 염증관련 질환치료제용 2,4-이중치환-5-아미노카르보닐-1,3-티아졸 유도체, 그의 제조방법 및 그를 유효성분으로 함유하는 ｓｐｃ 수용체 활성으로 유발되는 염증관련질환 치료제
KR102676631B1 (ko) 과민성 방광의 예방 또는 치료용 약학적 조성물
KR20150036385A (ko) 테트라히드로-이소후물론 유도체, 제조 방법 및 사용 방법
JP7360229B2 (ja) フェロトーシス阻害剤及びその用途
RU2586772C2 (ru) Фармацевтическая композиция для ингибирования апоптоза нейронов или нейродегенерации
KR101051077B1 (ko) 2-피페라지노-4,5-이중치환-1,3-티아졸 유도체, 그의 제조방법 및 그를 유효성분으로 함유하는 ｓｐｃ 수용체 활성으로 유발되는 염증관련질환 치료제
KR100916716B1 (ko) 3-클로로-5-치환-퀴녹살린-2-아민 유도체 및 약제학적으로허용 가능한 그의 염, 그의 제조방법 및 그를 유효성분으로함유하는 ｓｐｃ 수용체 활성으로 유발되는 염증관련 질환치료제
JPH072782A (ja) キノロン誘導体、その製造法およびそれを有効成分とする薬剤
KR20070006114A (ko) 리폭시제나아제에 대한 저해 활성을 갖는 신규벤즈이미다졸 유도체 화합물, 이의 제조방법 및 이를포함하는 천식의 치료 및 예방용 조성물

Legal Events

Date Code Title Description
HC9A Changing information about author(s)